Trends in Testosterone Replacement Therapy Use from 2003 to 2013 among Reproductive-Age Men in the United States
Abstract
Purpose:
Although testosterone replacement therapy use in the United States has increased dramatically in the last decade, to our knowledge trends in testosterone replacement therapy use among reproductive-age men have not been investigated. We assessed changes in testosterone replacement therapy use and practice patterns among 18 to 45-year-old American men from 2003 to 2013 and compared them to older men.
Materials and Methods:
This is a retrospective, cross-sectional analysis of men 18 to 45 and 56 to 64 years old who were enrolled in the Truven Health MarketScan® Commercial Claims Databases throughout each given calendar year from 2003 to 2013, including 5,094,868 men in 2013. Trends in the yearly rates of testosterone replacement therapy use were calculated using Poisson regression. Among testosterone replacement therapy users, the Cochran-Armitage test was used to assess temporal trends in age, formulation type, semen analysis and serum testosterone level testing during the 12 months preceding the documented use of testosterone replacement therapy.
Results:
Between 2003 and 2013, there was a fourfold increase in the rate of testosterone use among 18 to 45-year-old men from 29.2/10,000 person-years to 118.1/10,000 person-years (p <0.0001). Among testosterone replacement therapy users, topical gel formulations were initially most used. Injection use then doubled between 2009 and 2012 (23.5% and 46.2%, respectively) and surpassed topical gel use in 2013. In men 56 to 64 years old there was a statistically significant threefold increase in testosterone replacement therapy use (p <0.0001), which was significantly smaller than the fourfold increase in younger men (p <0.0001).
Conclusions:
In 2003 to 2013, testosterone replacement therapy use increased fourfold in men 18 to 45 years old compared to threefold in older men. This younger age group should be a focus for future studies due to effects on fertility and unknown long-term sequelae.
References
- 1 : Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med2013; 173: 1465. Google Scholar
- 2 : Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab2014; 99: 835. Google Scholar
- 3 : Recent trends in testosterone testing, low testosterone levels, and testosterone treatment among Veterans. Andrology2015; 3: 287. Google Scholar
- 4 : Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse. Med J Aust2013; 199: 548. Google Scholar
- 5 : Disease mongering of age-associated declines in testosterone and growth hormone levels. J Am Geriatr Soc2015; 63: 809. Google Scholar
- 6 : Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab2010; 95: 2536. Google Scholar
- 7 : Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation1988; 78: 539. Google Scholar
- 8 : In older men, higher plasma testosterone or dihydrotestosterone is an independent predictor for reduced incidence of stroke but not myocardial infarction. J Clin Endocrinol Metab2014; 99: 4565. Google Scholar
- 9 : Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation2004; 109: 2074. Google Scholar
- 10 : Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J2015; 36: 2706. Google Scholar
- 11 : Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med2014; 11: 1577. Google Scholar
- 12 : Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA2013; 310: 1829. Google Scholar
- 13 : Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One2014; 9: e85805. Google Scholar
- 14 : Comparative safety of testosterone dosage forms. JAMA Intern Med2015; 175: 1187. Google Scholar
- 15 Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management Advisory Committee (DSARM AC). Silver Spring: United States Food and Drug Administration2014. Google Scholar
- 16 : Medical testosterone: an iatrogenic cause of male infertility and a growing problem. Urology2015; 85: 1068. Google Scholar
- 17 : Testosterone use in the male infertility population: prescribing patterns and effects on semen and hormonal parameters. Fertil Steril2014; 101: 64. Google Scholar
- 18 : Empirical medical therapy for idiopathic male infertility: a survey of the American Urological Association. J Urol2012; 187: 973. Link, Google Scholar
- 19 Martinez G, Daniels K and Chandra A: Fertility of men and women aged 15-44 years in the United States: National Survey of Family Growth, 2006-2010. Natl Health Stat Report, April 12, 2012. Google Scholar
- 20 FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. Silver Spring: United States Food and Drug Administration2015. Google Scholar
- 21 : Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol2009; 55: 121. Google Scholar
- 22 AUA Position Statement on Testosterone Therapy. Linthicum Heights: American Urological Association2014. Google Scholar
- 23 : Ascertainment of testosterone prescribing practices in the VA. Med Care2015; 53: 746. Google Scholar
- 24 : Direct-to-consumer pharmaceutical advertising: therapeutic or toxic?. P T2011; 36: 669. Google Scholar
- 25 : Direct-to-consumer advertising in oncology. Oncologist2006; 11: 217. Google Scholar
- 26 Perrone M: Testosterone marketing frenzy draws skepticism. NBC News, September 9, 2012. Google Scholar
- 27 Singer N: Selling That New-Man Feeling. The New York Times, November 23, 2013. Google Scholar
- 28 Weintraub A: Why All Those Testosterone Ads Constitute Disease Mongering. Forbes, March 24, 2015. Google Scholar
- 29 Dobrow L: 2013 All-Star Large Pharma Marketing Team of the Year: AndroGel. Medical Marketing & Media, January 2, 2013. Google Scholar
- 30 News & Events: Testosterone Gel Safety Concerns Prompt FDA to Require Label Changes, Medication Guide. Silver Spring: United States Food and Drug Administration, May 7, 2009. Google Scholar
